

Update to OPAST/GNFS Ordering Procedures in Dx

Date: December 11th, 2025

Effective Date: December 15th, 2025

The Molecular Diagnostic Laboratory is implementing a **change to the ordering process for OPAST (Oncogenic Precision Assay Solid Tumor NGS) and GNFS (Lung Cancer Gene Fusion Panel) in Dx**. This update aims to optimize testing pathways while ensuring appropriate patient care.

Going forward, when OPAST/GNFS is ordered in Dx using the combined dropdown option, the testing will follow a streamlined reflex pathway:

- OPAST ngs panel is performed
- GNFS reflex logic
 - The fusion assay (GNFS) will be performed only if no pathogenic or likely pathogenic variants are detected by OPAST. This pathway does not require additional action from the requestor.
 - If a Tier I or II variant is detected, the lab will cancel the GNFS assay. A cancellation report stating that "GNFS test was not indicated based upon the OPAST result" will be issued.

We understand that clinical situations can vary. **If there is a medical necessity to proceed with GNFS regardless of the OPAST result, you may still order both OPAST and GNFS as separate line items.** In such cases, the GNFS will be performed even if OPAST yields a positive result. We believe this updated process will enhance efficiency in our diagnostic workflow.

For any questions, please contact:

Allison Cox, Ph.D.
Interim Director of the Molecular Diagnostic Laboratory, UR Medicine Labs
Phone: (585) 758-0456
Email: Allison_Cox@URMC.Rochester.edu

Paige Elliott
Supervisor, Molecular Diagnostic Laboratory
Phone: (585) 275-2709
Email: Paige_Elliott@urmc.rochester.edu